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Abstract
Serious psychological distress (SPD) can adversely impact health and quality of life after cancer. 
The purpose of this study is to examine the association between SPD and the receipt of preventive 
care services and cancer screening among survivors and adults without a cancer history. A total of 
12,564 cancer survivors and 160,023 adults without a cancer history as comparison group were 
identified from the population-based Medical Expenditure Panel Survey (2008–2015). SPD was 
assessed using the 6-item Kessler Psychological Distress Scale. We examined use of preventive 
care and cancer screening services in cancer survivors and comparison adults with/without SPD. 
Multivariable logistic regression models were conducted for each outcome: preventive service (i.e. 
blood pressure, cholesterol, influenza vaccination, routine and dental check-up) or cancer 
screening (i.e. mammography, Papanicolau test, colorectal cancer screening) adjusting for 
demographic, comorbidity, usual source of care covariates. Adjusted odds ratios and 95% 
confidence intervals were calculated. Prevalence of SPD was 9.8% in cancer survivors compared 
to 4.6% in comparison adults. Survivors with SPD were more frequent utilizers of medical care, 
reporting 10 or more visits to the doctor’s office in the past 12 months (29.3% vs. 14.1% without 
SPD). Having SPD was associated with lower odds of being up-to-date with preventive service use 
and cancer screening among age- and gender-eligible individuals. The magnitude of the effect was 
greater in adults’ age ≥65 years. Better coordination of care and patient-physician discussions are 
likely needed to improve delivery of recommended preventive services for persons with SPD.
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1. Introduction
For the estimated 15.5 million cancer survivors living in the United States today, 
survivorship can mean facing significant distress both during and long after diagnosis and 
treatment (Miller et al., 2016). Distress, as defined by the National Comprehensive Cancer 
Network (NCCN), is “a multifactorial unpleasant experience of a psychological (i.e. 
cognitive, behavioral, emotional), social, spiritual, and/or physical nature that may interfere 
with the ability to cope effectively with cancer, its physical symptoms, and its treatment” 
(NCCN Distress Management Version 2, 2017). Chronic elevated distress can have a 
disabling and detrimental effect on physical functioning, health (increasing the risk of 
cardiovascular disease, hypertension, and diabetes (Nyberg et al., 2014; Backe et al., 2012; 
Blanc-Lapierre et al., 2017)), and quality of life after cancer (NCCN Distress Management 
Version 2, 2017; Ng et al., 2015; Pinquart and Duberstein, 2010).
Serious psychological distress (SPD)—as a broad construct of depression, anxiety, panic, 
and existential fears—are common experiences among cancer survivors, who more 
frequently self-report medication use for anxiety and depression than persons without a 
history of cancer (Hawkins et al., 2017). A study by Han et al. (2015) estimated the 
prevalence of SPD in cancer survivors was 8.2% overall but higher in specific demographic 
subgroups (Han et al., 2015). Maintaining access to a usual source of care and ongoing 
preventive care after a cancer diagnosis is important to monitor after-effects of diagnosis/
treatment as survivors may be at an increased risk for recurrence or developing new cancers 
and other health conditions. Prior studies have found SPD among cancer survivors to be 
associated with greater overall health care use and health care costs (Han et al., 2015). 
Although persons with SPD may be heavier users of the health care system (Han et al., 
2015), the extent to which preventive care services are received during these office visits is 
unclear. Given that use of preventive services are heavily influenced by having health 
insurance or a usual source of health care and also age (Yabroff et al., 2013), in this report, 
we build on prior research (Han et al., 2015) to examine the association between SPD and 
the receipt of preventive care services, including cancer screening, by age and insurance 
status (Yabroff et al., 2013).
2. Methods
2.1. Data source
Data were obtained from the nationally representative Medical Expenditure Panel Survey 
(MEPS) Household Component survey (2008–2015) (Medical Expenditure Panel Survey, 
n.d.), which collects information on demographic characteristics, health status, insurance, 
and health care use from civilian, noninstitutionalized respondents aged ≥18 years. Annual 
response rates were between 47.7% and 59.3% during the analyzed survey years (Medical 
Expenditure Panel Survey, n.d.).
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2.2. Sample selection
Cancer survivors were identified from responses to the question “Has a doctor or health 
provider ever told you that you have a cancer or malignancy of any kind?” We excluded 
respondents with non-melanoma skin cancer. Individuals with missing SPD information 
(~13.4%) were also excluded, yielding a sample of 12,564 cancer survivors and 160,023 
without a cancer history. Age at cancer diagnosis was not publicly available in the dataset 
after 2012. Thus, years since cancer diagnosis, calculated by subtracting the reported age at 
cancer diagnosis from the age at the time of the survey, could not be measure after 2012.
SPD was determined by the 6-question scale developed by Kessler et al. to measure 
psychosocial distress (Kessler et al., 2002). Questions included: During the last 30 days, how 
often did you feel 1) nervous, 2) hopeless, 3) restless or fidgety, 4) so sad that nothing could 
cheer you up, 5) that everything was an effort, 6) worthless? Response options were: none of 
the time, a little, some, most, and all of the time, scored on a scale of 0 to 4, respectively. 
Scores were summed and an average score of ≥13 was identified as having SPD (Han et al., 
2015). This measure has been validated in other populations (Kessler et al., 2010) and had 
demonstrated good internal consistency and reliability (Han et al., 2015; Kessler et al., 2002, 
2003).
Cancer treatment in the past year was defined as having received chemotherapy or 
radiotherapy or a surgical procedure for a cancer condition in any setting (as available in 
outpatient visit and office-based medical provider visit files) or having a prescription for an 
anti-neoplastic medication in the Prescribed Medicines Files.
2.3. Outcome measures
Outcome measures included several variables indicative of receipt of preventive care 
services or as recommended by the U.S. Preventive Services Task Force (USPSTF) or 
Advisory Committee on Immunization Practices. We examined self-reported responses to 
having had the following services: blood pressure check within past 2 years; cholesterol 
check within past 2 years; influenza vaccination in the last year; routine check-up in the last 
year; and dental check-up at least once a year. Receipt of cancer screening was also 
examined among age- and gender-eligible individuals: mammogram within 2 years among 
women aged ≥40 years; Papanicolau (Pap) test within 3 years among women aged 21–65 
years; and colorectal cancer (CRC) screening (fecal occult blood test [FOBT] within 1 year, 
sigmoidoscopy within 5 years, or colonoscopy within 10 years) among adults aged 50–75 
years.
2.4. Statistical analysis
Descriptive statistics were calculated for sociodemographic characteristics (age, sex, race/
ethnicity, educational attainment, marital status) and health status. Data were stratified by 
SPD status among cancer survivors and adults without a cancer history.
According to the Andersen and Aday’s Behavioral Model of Health Service Use (Andersen, 
1995), there are factors that predispose individuals to access or seek care (i.e. age, sex, race/
ethnicity); enabling factors such as marital status, educational attainment, health insurance, 
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and having a usual source of care; and lastly, need factors based on cancer status, recency of 
cancer treatment, and presence of comorbidities. We used this model to guide selection of 
covariates.
Multivariable logistic regression models were conducted for each outcome, adjusting for 
age, sex, race/ethnicity, marital status, educational attainment, health insurance, treatment in 
the past year, having a usual source of care, and number of comorbidities. For specific 
preventive services (blood pressure, cholesterol check, and influenza vaccination), models 
additionally adjusted for number of doctor’s visits within the past year (0, 1, 2+). Given the 
age-related differences in insurance coverage, comorbidity, and use of the health care system 
(Yabroff et al., 2013), data further stratified by age and insurance were examined in detail 
(Appendix).
Proportions were age-adjusted to the 2000 U.S. census population using the direct method 
for age groups 18–34, 35–44, 45–54, 55–64, and ≥65 (Klein and Schoenborn, 2001). 
Adjusted odds ratios and 95% confidence intervals are reported in the tables. All analyses 
were conducted using SAS v 9.3 (Cary, NC) and SUDAAN v.11 to account for the MEPS 
complex survey design.
3. Results
3.1. Sample characteristics
Cancer survivors were older, more frequently insured, non-Hispanic White, and likely to 
have greater number of comorbidities than adults without a cancer history. Cancer survivors 
with SPD, in contrast, were generally younger and more commonly reported having only 
public insurance (49.6% vs 29.0%) or no insurance (9.1% vs 4.2%) compared to non-SPD 
survivors. SPD – regardless of cancer history – was more prevalent among women, those 
who were unmarried (never married/ widowed/divorced/separated), heavier weight (greater 
BMI), and physically inactive. Adults with SPD more often had lower educational 
attainment, lower income (100–200% of the federal poverty level or below), and were 
unemployed. Adults with SPD more often had ≥3 comorbidities and more often were 
smokers (Table 1). Most survivors were long-term survivors; about 1 in 8 cancer survivors 
with SPD (~13.9%) had treatment for cancer in the past year.
3.2. Cancer survivors with SPD and access to care and use of preventive care services
Cancer survivors were more likely to have SPD than adults without a cancer history (9.8% 
vs 4.6%), after adjusting for age differences (Table 2). Access to a usual source of care was 
highest among survivors without SPD (82.3%), followed by survivors with SPD (81.0%) and 
adults without a cancer history (73.9% no SPD; 76.4% with SPD). Survivors with SPD, 
compared to their counterparts without SPD, were more frequent utilizers of medical care, 
reporting 10 or more visits to the doctor’s office in the past 12 months (29.3% vs 14.1%). 
Adults without a cancer history with SPD similarly were more likely to frequent the doctor’s 
office in the past 12 months than those without a cancer history or SPD. Adults with and 
without a cancer history with SPD were generally less up-to-date with preventive care 
services compared to non-SPD counterparts.
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Similarly, in analyses adjusting for covariates, having SPD – regardless of cancer history – 
was associated with lower odds of being up-to-date with preventive service use, including 
cancer screening (Table 3). The magnitude of the effect was greater in adults age ≥65 years, 
among whom persons with SPD were much less likely than those without SPD to get 
screened for blood pressure and cholesterol in the last 2 years; influenza vaccination in the 
last year; have a routine exam in the past year; and appropriate breast and CRC screening 
(Table 3).
3.3. Cancer survivors with and without SPD by age and health insurance
Cancer survivors aged 18–64 years with SPD, compared to their counterparts without SPD, 
were more often uninsured (19.4% vs 11.8%) or had only public insurance (45.2% vs. 
16.2%) (Fig. 1). Access to care and preventive service varied by health insurance type for 
survivors with and without SPD in this younger age group. For example, survivors with SPD 
and private insurance more frequently reported being up-to-date with preventive services 
such as blood pressure and cholesterol check and a routine check-up in the last year 
compared to survivors without SPD, while less frequently reported being up-to-date with flu 
vaccination, dental check-up, and cancer screening services, though most of these 
differences were not statistically significant. Those with public insurance also followed a 
similar pattern (Appendix).
Among survivors aged ≥65 years, persons with SPD more frequently had Medicare only or 
Medicare and public insurance compared to those without SPD (39.7% vs 34.8% and 23.8% 
vs 7.6%, respectively; Fig. 1). Preventive service use was greatest for those with Medicare 
and supplemental private insurance, regardless of SPD status, compared to those with 
Medicare only or Medicare and public insurance. However, older survivors with SPD were 
less often up-to-date with preventive services and cancer screening than their non-SPD 
counterparts, regardless of insurance type (Appendix).
4. Discussion
Consistent with prior studies (Han et al., 2015), our analysis showed that the prevalence of 
SPD was greater among cancer survivors than the general population. Although persons with 
SPD (particularly those with a cancer history) mostly reported having access to a usual 
source of care and were more likely to be heavy users of health care per prior studies (Han et 
al., 2015; Pratt et al., 2007), our findings suggest there may be gaps in the type of services 
rendered during the encounters with the health care system. Persons with SPD, irrespective 
of a personal cancer history, were less likely to be up-to-date with preventive care and cancer 
screenings. Although this effect was more prominently noted in persons’ ≥65 years, a 
nontrivial proportion of cancer survivors with SPD aged 18–64 with private or public 
insurance were also not up-to-date on cancer screenings. Our findings highlight 
opportunities in cancer patient care to identify the need for and offer preventive services to 
cancer survivors and specifically individuals who might be experiencing SPD. Further 
efforts to understand the effects of implementing effective systems-based and patient-
centered interventions (such as electronic patient reminder systems and patient-oriented 
individual discussions, as clinically appropriate) to improve receipt of recommended 
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preventive services, will be important for improving outcomes for all adults and those with 
SPD.
4.1. Addressing preventive care and cancer screening
The goal of survivorship care is to enable survivors to live longer and healthier lives, but 
there are multi-level challenges to achieving this goal (Buchanan et al., 2015a). Cancer 
survivors have complex health concerns that include monitoring treatment-related side 
effects, evaluating existing or treatment-induced chronic conditions or neurocognition, 
surveillance for new primary cancers, and addressing psychosocial/emotional needs and 
general health/well-being (Hewitt et al., 2006; Buchanan et al., 2015b). In our survey 
sample, more than two-thirds of survivors had ≥2 comorbidities and adults with SPD often 
had ≥3 comorbidities with different profiles of comorbid conditions. Similar analyses have 
shown individuals with SPD more likely to have chronic obstructive pulmonary disease, 
heart disease, and diabetes compared to adults without SPD (Weissman et al., 2015). 
Although a cancer survivor may continue to see a primary care provider (Pollack et al., 
2009) and spend about 25 min on average with an oncologist (Guy and Richardson, 2012) 
during the clinical encounter, given the greater number of comorbidities (Ekwueme et al., 
2014) and battery of concerns that survivors face, preventive care concerns and behavioral 
health or intensive counseling-type activities may be time-prohibitive or overlooked. Prior 
research has demonstrated that few cancer survivors have discussions with any care 
providers about follow-up care, health behaviors (diet, exercise, quitting smoking), and 
emotional or social needs (Chawla et al., 2016). The complexity of their concerns could 
interfere with conversations that typically or should happen in follow-up care and wellness 
visits such as those about cancer screening services, immunizations, tobacco cessation, 
physical activity and other wellness services.
There is a great deal of heterogeneity in health trajectory (Eckstrom et al., 2013) by age and 
within age groups (ages 18–64 and ≥65 years). Given multimorbidities, the priority of 
preventive care concerns during an office visit may differ for younger vs older adults and 
those with SPD vs without SPD; and the indication for appropriate care is likely to vary 
based on the individual’s specific condition. For example, while the general assumption is 
that adults are likely to benefit from prevention and screening, the mortality benefits of 
screening an older adult may not always outweigh the potential harms of the test itself 
(Eckstrom et al., 2013). Additionally, younger and older adults may experience SPD 
differently due to distinctive life circumstances, social relationships, and other influencing 
factors (Holt-Lunstad et al., 2015). Lastly, differences exist in insurance coverage, access to 
care, and healthcare utilization between persons aged 18–64 vs. ≥65 (Yabroff et al., 2013).
It is important to note that while use of clinical preventive services may differ because of 
age, it should not be offered solely based on age. Not all 65-year-old or 70-year-old adults 
will deal with the same morbidity burden (Cho et al., 2013), functional status and life 
expectancy. Earlier analyses of a prospective cohort of healthy men (Yates et al., 2008) 
showed that healthy, 70-year-old men had a higher probability of living to age 90 (by not 
smoking, not having obesity, diabetes, and hypertension, and being active) than less healthy 
70-year-old men (Yates et al., 2008). A 2017 updated USPSTF review also found that 
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behavioral counseling is effective at improving adiposity/body mass index, blood pressure, 
and lipid levels for all ages (Patnode et al., 2017). Opportunity exists for more vigilance in 
following-up with adults and survivors that go beyond current efforts, distribution of 
survivorship care plans and/or referrals to appropriate and recommended services (Cancer 
Program Standards 2012: Ensuring Patient-Centered Care, n.d.). Patient-centered discussion 
and individualized attention within primary or specialized care settings will likely be 
beneficial.
For long-term cancer survivors, continued medical surveillance of screenable cancers are 
important because they are at elevated risk of second cancers (Berkowitz et al., 2011; 
Murphy et al., 2018). A recent study using cancer registry data found that about 25% of 
older (≥65 years) and 11% of younger cancer survivors had a prior history of cancer 
(Murphy et al., 2018), with most prior cancers unrelated to the second diagnosis. While the 
role of access to care and insurance is important to being up-to-date with preventive care and 
cancer screenings, our adjusted analyses showed that cancer survivors with SPD, regardless 
of age group, were less likely to be up-to-date on cancer screenings compared to their non-
SPD counterparts with the same insurance type. This is notable given that many cancers 
share etiologic pathways and environmental conditions that can influence the pathobiology 
of disease; for example, obesity is a risk factor for thirteen different cancers and similarly, 
human papilloma virus and tobacco are associated with several cancers (Murphy et al., 2018; 
Steele et al., 2017).
4.2. Addressing SPD
In our analysis, adults with SPD visited doctors more frequently. While our data do not 
allow us to examine the reasons for the healthcare visits and content of patient-provider 
discussions, the greater numbers of healthcare visits observed in this subgroup could be a 
symptom of the SPD. For example, adults may somaticize depressive symptoms and seek 
clinical care for experiencing non-specific concerns without realizing the possibility of 
having clinical depression (Bevilacqua et al., 2018). Other studies of adults with SPD have 
similarly found distress as a motivating factor for seeking healthcare (Weissman et al., 
2016).
Our cross-sectional study does not allow for causal inferences. However, SPD, stress, 
anxiety, and depression are arguably important to monitor given significant associations with 
inflammation and several metabolic diseases (Cuneo et al., 2017; Davis et al., 2018; 
Nagaraja et al., 2016). Heart disease and diabetes have been likened to post-traumatic stress 
disorder in cancer patients (Chan et al., 2018). There is mounting evidence of “social 
isolation” and depression (potentially characteristic in persons with SPD) as predictors of 
mortality similar to that of well-documented clinical factors (Pantell et al., 2013). Though 
the International Agency for Research on Cancer (Straif et al., n.d.) notes that there is still 
some work to be done specifically on the role of stress in disease onset or progression, the 
association between psychological status and physical health in cancer patients is a priority 
issue and one of continued interest for cancer control (Lengacher et al., 2014).
To address these concerns for survivors and adults without a cancer history, the clinical and 
public health community will need to better distinguish the underlying cause of distress, as 
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the appropriate intervention to alleviate SPD may differ by cause. For example, factors 
associated with cost of care may create anxiety and distress (Ell et al., 2008; Shankaran et 
al., 2018; Yabroff et al., 2016). In such cases, pilot interventions like the Oncology Financial 
Navigation Program (Shankaran et al., 2018), provides financial counseling at the onset of 
cancer diagnosis and has shown promise in easing anxiety. For SPD stemming from 
depression, loneliness or lack of social support, intervention programs such as Befriending 
(Siette et al., 2017) (which help to develop peer supportive relationships) or LISTEN 
(Theeke and Mallow, 2015) (focusing on concepts of cognitive behavioral therapy), though 
still under evaluation, have potential to improve health and minimize negative sequelae of 
SPD. Additionally, we need to understand reasons patients are not receiving preventive care 
services. For example, are patients substituting specialty care or condition-centric care for 
primary preventive care? The patient narrative on these issues is important for closing gaps 
in the delivery of clinical preventive care.
Our study has several limitations. First, our analysis relied on self-reported data and our 
findings are subject to measurement error (e.g. underreporting) and to recall bias. This bias 
may be stronger among older adults and could affect variables that determine cancer history, 
SPD, and preventive care and cancer screening use. Due to inadequate sample sizes and 
changes in data availability, there were limitations on the extent to which we could examine 
variation by cancer type, stage of disease, and on the recency of the cancer diagnosis. Lastly, 
in the absence of a complete view of an individual’s medical record including disease stage, 
we are unable to determine receipt of individual-level, guideline-concordant care, based on 
personal cancer treatment history and medical condition.
Our study also has many strengths. MEPS allows for nationally representative population-
based estimates of health utilization characteristics among cancer survivors and the general 
public. The MEPS has accompanying medical conditions file that captures verbatim text 
from respondents on medical conditions that are converted to International Classification of 
Diseases, Ninth revision, clinical modification (ICD-9-CM) codes. Thus, we verified that 
most individuals with SPD in our sample also had a corresponding ICD-9-CM code for 
depression and many had indicated taking antidepressants or psychotherapeutic agents at 
some point.
In summary, we observed that SPD was associated with lower preventive service use, 
notably among older adults and cancer survivors. Better coordination of care may be 
important for these populations. While distress screening and appropriate referrals for SPD 
may be indicators of quality care, greater attention to treatment of the conditions creating the 
distress and better patient-physician communication about care are steps to improving 
delivery of recommended preventive services.
Supplementary data to this article can be found online at https://doi.org/10.1016/j.ypmed.
2019.03.024.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Age-adjusted percentages† of cancer survivors with and without SPD** by age group and 
insurance type.
†Age-adjusted percentages to the 2000 U.S. census population using the direct method for 
age groups 18–34, 35–44, 45–54, 55–64, and ≥65.
**SPD: serious psychological distress.
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